Supplementary file

FIGURE 1. Efficacy of rifapentine with 1200 mg dosage for DS-TB




FIGURE 2. Sputum conversion rate rifapentine with 1200 mg dosage compared to standard regimen for DS-TB

| | Converted | | Not Converted | | Odds Ratio | | Odds Ratio | | | |
|--|-----------|-------|---------------|-------|------------|-------------------------|------------|----------------------|-----------------|---------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% CI | | M-H, Random, 95% CI | | |
| Dorman 2014 (RPT 15Mg/Kg) | 59 | 66 | 7 | 66 | 33.3% | 71.04 [23.46, 215.14] | | | | |
| Dorman 2014 (RPT 20Mg/Kg) | 54 | 57 | 3 | 57 | 29.6% | 324.00 [62.59, 1677.23] | | | | \rightarrow |
| Dorman 2021 (RPT) | 645 | 838 | 193 | 838 | 37.1% | 11.17 [8.90, 14.02] | | | • | |
| Total (95% CI) | | 961 | | 961 | 100.0% | 56.03 [7.83, 401.15] | | | _ | |
| Total events | 758 | | 203 | | | | | | | |
| Heterogeneity: $Tau^2 = 2.71$; $Chi^2 = 25.51$, $df = 2$ (P < 0.00001); $I^2 = 92\%$ Test for overall effect: $Z = 4.01$ (P < 0.0001) | | | | | | | 0.01 | 0.1 Not Converted | 10 Converted | 100 |

FIGURE 3. Meta-analysis comparing the safety of rifapentine-containing regimen versus standard regimen using random effect model

